Post-marketing Surveillance of Donepezil Hydrochloride- Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease
Post-marketing Surveillance of Donepezil Hydrochloride- Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease
To investigate the clinical safety and effectiveness of donepezil hydrochloride administration in patients with mild or moderate Alzheimer's Disease
Inclusion criteria;
Patients diagnosed as Alzheimer's Disease by Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).
Patients diagnosed as mild or moderate Alzheimer's Disease, applicable to Functional Assessment Staging (FAST) score 4 or 5.
Exclusion criteria;
Patients who used Aricept within 3 months prior to dosing.
Patients registered this survey before.
Patients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.
Kita, Kagawa-ken, Japan
Kitamorokata, Miyazaki, Japan
Bunkyo, Tokyo, Japan